Association between APOE epsilon 2/epsilon 3/epsilon 4 polymorphism and disability severity in a national long-term
Alexander Kulminski1, Svetlana V Ukraintseva, Konstantin G Arbeev
1Center for Population Health and Aging, Duke University Population Research Institute, Department of Sociology, Duke University, Trent Hall, Room 002, Durham, NC 27708, USA. Alexander.Kulminski@duke.edu
Background:
early studies reported controversial findings on association of apolipoprotein E (APOE) polymorphism with disability.
Objective:
to analyse sex-specific associations of APOE genotypes with impairments in (instrumental) activities of daily living [(I)ADL] and mortality.
Design:
population-based 1999 National Long Term Care Survey (NLTCS) of the US older (65+) individuals.
Participants:
genetic data are available for 1,805 individuals.
Methods:
each of six genotypes of three common alleles of the APOE locus (epsilon 2, epsilon 3 and epsilon 4) was tested on the association with a disability index or mortality.
Results:
APOE epsilon 3/epsilon 3 genotype significantly decreases odds ratio (OR) for IADL disability in males [OR = 0.48; 95% Confidence Interval (CI) 0.31-0.76] while it exhibits no association in females. The OR for ADL disability is 0.19 (CI 0.04-0.99) for epsilon 4/epsilon 4 female carriers. The epsilon 2/epsilon 3 genotype increases the chances of IADL disability for males (OR = 2.33; CI 1.28-4.25). No significant association between APOE polymorphism and mortality was found. A surprising observation was that epsilon 4/epsilon 4 female carriers have a 5.3 times lower chance of having ADL disability than non-epsilon 4/epsilon 4-carriers.
Conclusions:
association of the APOE polymorphism with disability and lack of association with mortality support the view that APOE gene actions may be more significant as modulators of frailty than of longevity.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
01:29Alzheimer Disease l: Introduction
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu